Spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3 (SCA3) is a condition characterized by progressive problems with movement. People with this condition initially experience problems with coordination and balance (ataxia). Other early signs and symptoms of SCA3 include speech difficulties, uncontrolled muscle tensing (dystonia), muscle stiffness (spasticity), rigidity, tremors, bulging eyes, and double vision. People with this condition may experience sleep disorders such as restless leg syndrome or REM sleep behavior disorder. Restless leg syndrome is a condition characterized by numbness or tingling in the legs accompanied by an urge to move the legs to stop the sensations. REM sleep behavior disorder is a condition in which the muscles are active during the dream (REM) stage of sleep, so an affected person often acts out his or her dreams. These sleep disorders tend to leave affected individuals feeling tired during the day.

Over time, individuals with SCA3 may develop loss of sensation and weakness in the limbs (peripheral neuropathy), muscle cramps, muscle twitches (fasciculations), and swallowing difficulties. Individuals with SCA3 may have problems with memory, planning, and problem solving.

Signs and symptoms of the disorder typically begin in mid-adulthood but can appear anytime from childhood to late adulthood. People with SCA3 eventually require wheelchair assistance. They usually survive 10 to 20 years after symptoms first appear.

Frequency

The prevalence of SCA3 is unknown. This condition is thought to be the most common type of spinocerebellar ataxia; however, all types of spinocerebellar ataxia are relatively rare. SCA3 appears to be more common in certain populations, such as some Aboriginal Australian populations.

Causes

Mutations in the ATXN3 gene cause SCA3. The ATXN3 gene provides instructions for making an enzyme called ataxin-3, which is found in cells throughout the body. Ataxin-3 is involved in a mechanism called the ubiquitin-proteasome system that destroys and gets rid of excess or damaged proteins. The molecule ubiquitin is attached (bound) to unneeded proteins, which tags them to be broken down (degraded) within cells. Ataxin-3 removes the ubiquitin from these unwanted proteins just before they are degraded so that the ubiquitin can be used again. Researchers believe that ataxin-3 also may be involved in regulating the first stage of protein production (transcription).

The ATXN3 gene mutations that cause SCA3 involve a DNA segment known as a CAG trinucleotide repeat. This segment is made up of a series of three DNA building blocks (cytosine, adenine, and guanine) that appear multiple times in a row. Normally,
the CAG segment is repeated 12 to 43 times within the gene. Most people have fewer than 31 CAG repeats. In people with SCA3, the CAG segment is repeated more than 50 times. People who have 44 to 52 CAG repeats are described as having an "intermediate repeat." These individuals may or may not develop SCA3. People with 75 or fewer repeats tend to first experience signs and symptoms of SCA3 in mid-adulthood, while people with around 80 repeats usually have signs and symptoms by their teens.

An increase in the length of the CAG segment leads to the production of an abnormally long version of the ataxin-3 enzyme that folds into the wrong 3-dimensional shape. This nonfunctional ataxin-3 enzyme cannot remove ubiquitin from proteins that are no longer needed. As a result, these unwanted proteins, along with ubiquitin and ataxin-3, cluster together to form clumps (aggregates) within the nucleus of the cells. It is unclear how these aggregates affect cell function, because they are found in healthy cells as well as those that die.

Nerve cells (neurons) and other types of brain cells are most affected by mutations in the ATXN3 gene. SCA3 is associated with cell death in the part of the brain that is connected to the spinal cord (the brainstem), the part of the brain involved in coordinating movements (the cerebellum), and other areas of the brain. This condition is also associated with the death of neurons in the spinal cord. Over time, the loss of cells in the brain and spinal cord cause the signs and symptoms characteristic of SCA3.

**Inheritance Pattern**

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one parent with the condition.

As the altered ATXN3 gene is passed down from one generation to the next, the length of the CAG trinucleotide repeat often increases. A larger number of repeats is usually associated with an earlier onset and faster progression of signs and symptoms. This phenomenon is called anticipation. Anticipation may be more prominent when the ATXN3 gene is inherited from a person's father (paternal inheritance) than when it is inherited from a person's mother (maternal inheritance).

In rare cases, individuals have been reported with expanded CAG repeats on both copies of the ATXN3 gene in each cell. These people tend to have more severe signs and symptoms than people with only one mutation, and features of the condition appear in childhood.

**Other Names for This Condition**

- Azorean ataxia
- Azorean disease
- Machado-Joseph disease
• MJD
• SCA3

Diagnosis & Management

Genetic Testing Information
• What is genetic testing?
  /primer/testing/genetictesting
• Genetic Testing Registry: Azorean disease

Research Studies from ClinicalTrials.gov
• ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22spinocerebellar+ataxia+type+3%22+OR+%22Spino%20cerebellar+Ataxias%22

Other Diagnosis and Management Resources
• GeneReview: Spinocerebellar Ataxia Type 3
  https://www.ncbi.nlm.nih.gov/books/NBK1196

Additional Information & Resources

Health Information from MedlinePlus
• Encyclopedia: Movement--Uncoordinated
  https://medlineplus.gov/ency/article/003198.htm
• Health Topic: Balance Problems
  https://medlineplus.gov/balanceproblems.html
• Health Topic: Cerebellar Disorders
  https://medlineplus.gov/cerebellardisorders.html
• Health Topic: Movement Disorders
  https://medlineplus.gov/movementdisorders.html

Genetic and Rare Diseases Information Center
• Spinocerebellar ataxia 3

Additional NIH Resources
• National Institute of Neurological Disorders and Stroke: Ataxias and Cerebellar or Spinocerebellar Degeneration Information Page
  https://www.ninds.nih.gov/Disorders/All-Disorders/Ataxias-and-Cerebellar-or-Spinocerebellar-Degeneration-Information-Page
Educational Resources

- Johns Hopkins Medicine Department of Neurology and Neurosurgery: What is Ataxia?
  https://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/ataxia/conditions/

- MalaCards: machado-joseph disease
  https://www.malacards.org/card/machado_joseph_disease

- Merck Manual Consumer Version: Coordination Disorders

- Orphanet: Machado-Joseph disease type 1
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=276238

- Orphanet: Spinocerebellar ataxia type 3
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=98757

- Washington University, St. Louis: Neuromuscular Disease Center
  https://neuromuscular.wustl.edu/ataxia/domatax.html#mjd

Patient Support and Advocacy Resources

- Family Caregiver Alliance
  https://www.caregiver.org/

- MJD Foundation (Australia)
  http://mjd.org.au/

- National Ataxia Foundation
  https://ataxia.org/

- National Organization for Rare Disorders (NORD): Autosomal Dominant Hereditary Ataxia
  https://rarediseases.org/rare-diseases/autosomal-dominant-hereditary-ataxia/

Clinical Information from GeneReviews

- Spinocerebellar Ataxia Type 3
  https://www.ncbi.nlm.nih.gov/books/NBK1196

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Spinocerebellar+Ataxias%5BMAJR%5D%29+AND+%28%28spinocerebellar+ataxia+type+3%5BTIAB%5D%29+OR+%28macha
Catalog of Genes and Diseases from OMIM

- MACHADO-JOSEPH DISEASE
  http://omim.org/entry/109150

Medical Genetics Database from MedGen

- Azorean disease

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20130417

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19811945
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2818316/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17894834

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19934555

Reprinted from Genetics Home Reference:

Reviewed: February 2019
Published: December 10, 2019

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services